









Markets
/
Stocks
/
nasdaq-sera
/

Sera Prognostics Inc

SERA

3.300USD

+0.100+3.13%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

125.49MMarket Cap

LossP/E TTM



Sera Prognostics Inc

3.300

+0.100+3.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

67 / 167

Overall Ranking

193 / 4720

Industry

Professional & Commercial Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.

Growing

The company is in a growing phase, with the latest annual income totaling USD 77.00K.

Fairly Valued

The company’s latest PE is -3.90, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.90M shares, decreasing 5.18% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.16M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.70.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.54, which is lower than the Professional & Commercial Services industry's average of 7.40. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 17.00K, representing a year-over-year decrease of 29.17%, while its net profit experienced a year-over-year decrease of 3.10%.

Score

Industry at a Glance

Previous score

5.54

Change



Financials

7.57

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.88

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

3.43

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.06

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Professional & Commercial Services industry's average of 2.38. Its current P/E ratio is -3.79, which is -38.40% below the recent high of -2.33 and -70.15% above the recent low of -6.44.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/167

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.00, which is higher than the Professional & Commercial Services industry's average of 7.62.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

0.000

Target Price

0.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Sera Prognostics Inc

SERA

Block Inc

XYZ

PayPal Holdings Inc

PYPL

Fiserv Inc

Global Payments Inc

GPN

United Rentals Inc

URI

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.17, which is higher than the Professional & Commercial Services industry's average of 7.29. Sideways: Currently, the stock price is trading between the resistance level at 3.77 and the support level at 2.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.17

Change

0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Neutral

RSI(14)

62.928

Neutral

STOCH(KDJ)(9,3,3)

50.413

Buy

ATR(14)

0.250

Low Volatility

CCI(14)

40.738

Neutral

Williams %R

44.547

Buy

TRIX(12,20)

0.823

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.178

Buy

MA10

3.140

Buy

MA20

3.105

Buy

MA50

2.852

Buy

MA100

2.511

Buy

MA200

3.932

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is lower than the Professional & Commercial Services industry's average of 7.77. The latest institutional shareholding proportion is 83.31%, representing a quarter-over-quarter increase of 2.37%. The largest institutional shareholder is The Vanguard, holding a total of 1.16M shares, representing 3.14% of shares outstanding, with 17.89% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

5.50M

Chione, Ltd.

2.40M

+35.28%

abrdn Inc.

1.24M

Anthem, Inc.

2.20M

aMoon Fund

1.91M

-35.83%

Vivo Capital, LLC

1.65M

Domain Associates, L.L.C.

1.25M

The Vanguard Group, Inc.

Star Investors

1.28M

+1.80%

Critchfield (Gregory C)

822.27K

+1.93%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.00, which is lower than the Professional & Commercial Services industry's average of 4.25. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.